US Stock MarketDetailed Quotes

NAMSW NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)

Watchlist
  • 11.522
  • +0.892+8.39%
Close Mar 27 16:00 ET
0Market Cap0.00P/E (TTM)

About NEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM) Company

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Company Profile

SymbolNAMSW
Company NameNEWAMSTERDAM PHARMA CO NV C/WTS (TO PUR COM)
Listing Date02/08/2021
Founded2022
CEODr. Michael Harvey Davidson, M.D.
MarketNASDAQ
Employees29
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
AddressGooimeer 2-35
CityNaarden
ProvinceNoord-Holland
CountryNetherlands (the)
Zip Code1411 DC
Phone31-35-206-29-71

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Michael Harvey Davidson, M.D.
  • Chief Executive Officer and Director
  • 5.81M
  • Douglas F. Kling
  • Chief Operating Officer
  • --
  • Ian Somaiya
  • Chief Financial Officer
  • 3.55M
  • Dr. Johannes Jacob Pieter Kastelein, M.D.
  • Chief Scientific Officer and Director
  • 2.98M
  • Dr. Marc Ditmarsch, M.D.
  • Chief Development Officer
  • --
  • Louise Kooij
  • Chief Accounting Officer
  • --
  • William H. Lewis
  • Chairman of the Board
  • --
  • Juliette Audet
  • Vice Chairman of the Board
  • 45.63K
  • Willian H Lewis
  • Lead Independent Chairman of the Board
  • --
  • Janneke van der Kamp
  • Director
  • 134.66K
  • Dr. James N. Topper, M.D.,PhD
  • Independent Director
  • 40.00K
  • Louis G. Lange, M.D.
  • Independent Director
  • 339.05K
  • John W. Smither
  • Independent Director
  • 138.83K
  • Sander Slootweg
  • Independent Director
  • 48.00K
  • Dr. Nicholas Downing, M.D.
  • Independent Director
  • 47.33K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg